10-Q: Harvard Bioscience Reports Q2 2024 Results Amidst Market Softening

Harvard Bioscience's Q2 2024 results show a decrease in revenue compared to the same period last year, impacted by softening global demand and reduced sales to contract research organizations.

Summary

• Harvard Bioscience reported a net loss of $2.9 million for the three months ended June 30, 2024, compared to a net loss of $0.98 million for the same period in 2023.
• Revenue decreased by 19.7% to $23.1 million in Q2 2024, down from $28.8 million in Q2 2023.
• The company's gross profit also decreased by 20.7% to $13.2 million, with a gross margin of 57.2% compared to 58.0% in the prior year.
• Operating expenses were $15.3 million, slightly down from $15.9 million in the same quarter of 2023.
• For the six months ended June 30, 2024, the net loss was $7.6 million, compared to a net loss of $0.36 million in the first half of 2023.
• Six-month revenue decreased by 18.9% to $47.6 million, down from $58.7 million in the first half of 2023.
• The company's gross profit for the first six months of 2024 was $28.0 million, with a gross margin of 58.8%, compared to $35.0 million and 59.6% respectively in the first half of 2023.
• The company sold all of its remaining shares of Harvard Apparatus Regenerative Technology, Inc. (HRGN) during the six months ended June 30, 2024, resulting in a loss of $1.6 million.
• The company received $3.2 million in employee retention credit refunds during the six months ended June 30, 2024.
• The company amended its credit agreement on August 6, 2024, modifying financial covenants and increasing the applicable interest rate margin by 50bps if the consolidated net leverage ratio is greater than 3.0.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like reduced expenses and employee retention credits, but the overall tone is negative due to decreased revenue, gross profit, and net loss. The company is facing significant headwinds in the current economic environment.

Positives

• The company received $3.2 million in employee retention credit refunds during the six months ended June 30, 2024.
• Sales and marketing expenses decreased by $0.8 million in Q2 2024 and $0.9 million in the first half of 2024, primarily due to lower compensation and travel costs.
• Interest expense decreased by $0.2 million in Q2 2024 and $0.4 million in the first half of 2024, primarily due to lower average borrowings during the period.

Negatives

• Q2 2024 revenue decreased by 19.7% year-over-year to $23.1 million.
• Gross profit for Q2 2024 was $13.2 million, a 20.7% decrease compared to Q2 2023.
• The company reported a net loss of $2.9 million for Q2 2024.
• For the six months ended June 30, 2024, revenue decreased by 18.9% to $47.6 million.
• The company recorded a loss of $1.6 million on the sale of HRGN shares in the first half of 2024.
• The company's gross margin decreased to 57.2% for the three months ended June 30, 2024, compared with 58.0% for the three months ended June 30, 2023.

Risks

• The company's business is affected by global and regional economic trends and uncertainties, including inflationary pressure, higher interest rates, and fluctuations in exchange rates.
• The company has experienced softening in certain international markets, especially in China and the Asia-Pacific region.
• Reduced demand from biotechnology and pharmaceutical company customers due to increased cost of capital and reduced spending following the COVID-19 pandemic is impacting the business.
• Delays in government funding for certain customers are also affecting the company's performance.

Future Outlook

Based on current operating plans, the company expects that available cash, cash generated from operations, and debt capacity will be sufficient to finance current operations and capital expenditures for at least the next 12 months.

Industry Context

The company's performance is being affected by a softening of certain international markets, especially in China and the Asia-Pacific region, as well as by delays in government funding for certain customers. The company is also experiencing reduced demand from biotechnology and pharmaceutical company customers due to increased cost of capital and reduced spending following the COVID-19 pandemic.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects to benchmark against.
• However, the document does note that the company's business is affected by global and regional economic trends and uncertainties, including inflationary pressure, higher interest rates, and fluctuations in exchange rates, which are common challenges across the industry.
• The company's reduced demand from biotechnology and pharmaceutical company customers is also a trend seen across the industry due to increased cost of capital and reduced spending following the COVID-19 pandemic.

Legal Proceedings

• The company is involved in various claims and legal proceedings arising in the ordinary course of business, but the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and net loss.
• Employees may be affected by restructuring and headcount reductions.
• Customers may experience changes in product availability or service levels.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company will continue to monitor the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies.
• The company will continue to align its cost base and infrastructure with customer needs and its strategic plans.

Key Dates

Keywords

Harvard Bioscience, financial results, quarterly report, revenue, net loss, gross profit, operating expenses, credit agreement, employee retention credit, marketable equity securities, biotechnology, pharmaceutical, contract research organizations